On 20 March, Athira Pharma, a clinical-stage biopharmaceutical company aiming to restore neuronal health in neurodegenerative diseases presented the study overview and baseline data from its ACT-AD Phase II clinical trial at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Diseases (AD/PD™ 2022). This 26-week study is a randomised, double-blind and placebo-controlled trial evaluating fosgonimeton (ATH-1017) for the treatment of mild-to-moderate Alzheimer’s disease (AD). Fosgonimeton is an investigational drug designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, to impact neurodegeneration and regenerate brain tissue. 77 participants have been enrolled in the US and Australia. The mean age is 71.4 years, with 50.6% female and 49.4% male. This includes 31 participants with mild AD and 46 with moderate AD. They were randomly assigned to receive a daily subcutaneous injection of either ATH-1017 at low-dose (40 mg/day), ATH-1017 at high-dose (70 mg/day), or a placebo. At a preliminary data cut, 57 participants completed the study and approximately 14% discontinued prior to study completion. Top-line data are expected in the second half of 2022.
